Increasing Prevalence of Cardiovascular Diseases to Augment Growth of Acute Heart Failure (AHF) Therapeutics Market KhelPanda – KhelPanda

Acute heart failure is a medical emergency that involves sudden, permanent cessation of cardiac function (also called ventricular fibrillation). Acute heart failure most often develops due to a rupture or leaky blood vessel somewhere in the heart. This can happen either at the heart site itself, such as at the coronary artery, or at the lung level, such as at the aortic valve. As a result of the rupture, blood is pooling at the heart site and the blood flow is markedly reduced. As this pooling continues, blood pressure drops causing a decrease in cardiac output and, as the problem worsens, shock and death occur.

Click Here To Get Free Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1910

Note:*TheSample Copy Includes

1) Table of Content (ToC), 2) Research Framework of the actual report, and 3) Research Methodology.

Market Dynamics

Increasing prevalence of cardiovascular diseases is expected to propel growth of the global acute heart failure (AHF) therapeutics market. For instance, according to the American Heart Associations Heart and Stroke Statistics 2020 Update, by 2035, 45.1% of the U.S population is projected to have some form of cardiovascular disease. Moreover, increasing geriatric population is also expected to aid in growth of the market. For instance, according to United Nations Population Fund, geriatric population in Asia Pacific is expected to triple between 2010 and 2050 to reach 1.3 billion people by 2050.

High prevalence of heart failure is also expected to propel growth of the global acute heart failure (AHF) therapeutics market. For instance, according to the study, Global epidemiology and future trends of heart failure, published in AME Medical Journal in June 2020, heart failure poses the largest burden after 60 years of age and both prevalence and YLDs have increased by 3.9% and 4.5% in very elderly people during the last 28 years. Moreover, R&D in acute heart failure (AHF) therapeutics is also expected to aid in growth in the market. For instance, in November 2020, a clinical trial by Brigham and Womens Hospital and sponsored by Lexicon Pharmaceuticals, a biopharmaceutical company based in the U.S., reported that sotagliflozin, a combination sodium/glucose cotransporter 1 and 2 (SGLT1/2) inhibitor, resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo.

Buy This Research Study Report With Flat US $2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/1910

Major Key Players Are: Novartis AG,Cardiorentis AG,Bristol-Myers Squibb Company,Amgen Inc., Bayer AG, Cytokinetics, Inc., Merck & Company, Inc., Ono Pharmaceutical Co., Ltd., and Pfizer Inc.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Phone: US +12067016702 / UK +4402081334027 Email: sales@coherentmarketinsights.com

More here:
Increasing Prevalence of Cardiovascular Diseases to Augment Growth of Acute Heart Failure (AHF) Therapeutics Market KhelPanda - KhelPanda